https://www.cnn.com/2021/10/01/politics/blinken-cybersecurity-alliance/index.html
Roth Capital Maintains Buy on DiaMedica Therapeutics, Lowers Price Target to $32
Roth Capital analyst Elemer Piros maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and lowers the price target from $38 to $32.